FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1551637372> ?p ?o ?g. }

• W1551637372 endingPage "430" @default.
• W1551637372 startingPage "422" @default.
• W1551637372 abstract "Objectives: Previous prognostic factor models for metastatic renal cell carcinoma (mRCC) have not included erythrocyte sedimentation rate (ESR). We designed the present study to evaluate the prognostic value of ESR for mRCC patients treated with sorafenib. Methods: Sorafenib was given to 83 patients with clear cell mRCC. Serum ESR was tested before treatment and every 4 weeks after first administration of sorafenib. Oncological evaluation was carried out every 8 weeks. Analyzed factors included age, sex, performance status, method of nephrectomy, number of metastatic organs, anemia, lactate dehydrogenase, corrected calcium, albumin, baseline ESR level and ESR kinetics status. Kaplan–Meier and Cox regression analyses on progression‐free survival (PFS) were carried out. Results: Baseline ESR levels ranged from 3 to 154 mm/h, and 43 (41.0%) patients had an ESR level higher than 40 mm/h. Median PFS was 10.0 months (95% CI 7.6–12.4 months). Dividing the cohort into three groups according to ESR kinetics status, median PFS was 27 months in the decreased ESR group, 12 months in the stable ESR group and 6 months in the increased ESR group. Performance status, time from diagnoses to sorafenib treatment, number of metastatic organs and ESR kinetics were independent predictors for PFS in multivariable Cox regression model analysis, with an area under the curve of 0.865 in a binary logistic regression model of 12‐month PFS probability. Conclusions: ESR kinetics can be useful to monitor the treatment response and to predict PFS for mRCC patients treated with sorafenib as second‐line therapy." @default.
• W1551637372 created "2016-06-24" @default.
• W1551637372 creator A5000862445 @default.
• W1551637372 creator A5007183896 @default.
• W1551637372 creator A5010860795 @default.
• W1551637372 creator A5014398628 @default.
• W1551637372 creator A5018107666 @default.
• W1551637372 creator A5024778776 @default.
• W1551637372 creator A5037969914 @default.
• W1551637372 creator A5062711588 @default.
• W1551637372 creator A5066367553 @default.
• W1551637372 creator A5088933673 @default.
• W1551637372 date "2011-04-11" @default.
• W1551637372 modified "2023-10-16" @default.
• W1551637372 title "Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib" @default.
• W1551637372 cites W1771354333 @default.
• W1551637372 cites W1963741397 @default.
• W1551637372 cites W1965037168 @default.
• W1551637372 cites W1971358860 @default.
• W1551637372 cites W1971894005 @default.
• W1551637372 cites W1975946590 @default.
• W1551637372 cites W1992532818 @default.
• W1551637372 cites W1998026546 @default.
• W1551637372 cites W1999966467 @default.
• W1551637372 cites W2024251485 @default.
• W1551637372 cites W2034269086 @default.
• W1551637372 cites W2046252805 @default.
• W1551637372 cites W2082331198 @default.
• W1551637372 cites W2084778105 @default.
• W1551637372 cites W2100669312 @default.
• W1551637372 cites W2115201803 @default.
• W1551637372 cites W2116554142 @default.
• W1551637372 cites W2118677643 @default.
• W1551637372 cites W2135400147 @default.
• W1551637372 cites W2135953817 @default.
• W1551637372 cites W2137822543 @default.
• W1551637372 cites W2138822094 @default.
• W1551637372 cites W2143813821 @default.
• W1551637372 cites W2149456801 @default.
• W1551637372 cites W2153867442 @default.
• W1551637372 cites W2156503630 @default.
• W1551637372 cites W60629781 @default.
• W1551637372 doi "https://doi.org/10.1111/j.1442-2042.2011.02761.x" @default.
• W1551637372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21481012" @default.
• W1551637372 hasPublicationYear "2011" @default.
• W1551637372 type Work @default.
• W1551637372 sameAs 1551637372 @default.
• W1551637372 citedByCount "12" @default.
• W1551637372 countsByYear W15516373722012 @default.
• W1551637372 countsByYear W15516373722013 @default.
• W1551637372 countsByYear W15516373722014 @default.
• W1551637372 countsByYear W15516373722015 @default.
• W1551637372 countsByYear W15516373722016 @default.
• W1551637372 countsByYear W15516373722020 @default.
• W1551637372 crossrefType "journal-article" @default.
• W1551637372 hasAuthorship W1551637372A5000862445 @default.
• W1551637372 hasAuthorship W1551637372A5007183896 @default.
• W1551637372 hasAuthorship W1551637372A5010860795 @default.
• W1551637372 hasAuthorship W1551637372A5014398628 @default.
• W1551637372 hasAuthorship W1551637372A5018107666 @default.
• W1551637372 hasAuthorship W1551637372A5024778776 @default.
• W1551637372 hasAuthorship W1551637372A5037969914 @default.
• W1551637372 hasAuthorship W1551637372A5062711588 @default.
• W1551637372 hasAuthorship W1551637372A5066367553 @default.
• W1551637372 hasAuthorship W1551637372A5088933673 @default.
• W1551637372 hasConcept C126322002 @default.
• W1551637372 hasConcept C126894567 @default.
• W1551637372 hasConcept C143998085 @default.
• W1551637372 hasConcept C151956035 @default.
• W1551637372 hasConcept C181199279 @default.
• W1551637372 hasConcept C185592680 @default.
• W1551637372 hasConcept C2777318727 @default.
• W1551637372 hasConcept C2777472916 @default.
• W1551637372 hasConcept C2778019345 @default.
• W1551637372 hasConcept C2778143017 @default.
• W1551637372 hasConcept C2778248108 @default.
• W1551637372 hasConcept C2778695046 @default.
• W1551637372 hasConcept C2779984678 @default.
• W1551637372 hasConcept C2780091579 @default.
• W1551637372 hasConcept C2780227381 @default.
• W1551637372 hasConcept C2780739268 @default.
• W1551637372 hasConcept C29730261 @default.
• W1551637372 hasConcept C3019894029 @default.
• W1551637372 hasConcept C31760486 @default.
• W1551637372 hasConcept C50382708 @default.
• W1551637372 hasConcept C55493867 @default.
• W1551637372 hasConcept C71924100 @default.
• W1551637372 hasConcept C90924648 @default.
• W1551637372 hasConceptScore W1551637372C126322002 @default.
• W1551637372 hasConceptScore W1551637372C126894567 @default.
• W1551637372 hasConceptScore W1551637372C143998085 @default.
• W1551637372 hasConceptScore W1551637372C151956035 @default.
• W1551637372 hasConceptScore W1551637372C181199279 @default.
• W1551637372 hasConceptScore W1551637372C185592680 @default.
• W1551637372 hasConceptScore W1551637372C2777318727 @default.
• W1551637372 hasConceptScore W1551637372C2777472916 @default.
• W1551637372 hasConceptScore W1551637372C2778019345 @default.
• W1551637372 hasConceptScore W1551637372C2778143017 @default.

• next